Julien Fleurence
About Julien Fleurence
Julien Fleurence is a Product Development Scientist at Instil Bio, specializing in the development of clinical grade CAR-T cells and gene editing strategies. He holds a PhD in Immunology and Oncology from Université de Nantes and has extensive experience in the biotech industry, particularly in glioblastoma multiforme research.
Work at Instil Bio
Julien Fleurence has been employed at Instil Bio as a Product Development Scientist since 2021. In this role, he focuses on the development of clinical grade CAR-T cells and gene editing strategies. His work involves collaboration with GMP facilities for retroviral transduction processes. He utilizes multi-parameter flow cytometry for immunophenotyping, contributing to the advancement of therapies in the biotech sector.
Education and Expertise
Julien Fleurence holds a Doctor of Philosophy (PhD) in Immunology and Oncology from Université de Nantes, which he completed from 2013 to 2017. He also earned a Doctor of Pharmacy from the same institution, studying from 2006 to 2013. Additionally, he obtained a Master Degree in Immunology from Université Paris-Sud in 2013. His expertise includes designing and analyzing in vitro assays, such as XCELLigence and 51Chromium for cytotoxicity, and Luminex for cytokine analysis.
Background
Julien Fleurence has a diverse background in the field of biomedical research. He completed various internships, including a PharmD and PhD internship at Inserm, where he worked for four years from 2013 to 2017. He also gained experience through hospital internships at Hôtel Dieu CHU Nantes and Kaiser-Franz-Josef-Spital in 2011 and 2012, respectively. His postdoctoral fellowship at Baylor College of Medicine from 2018 to 2020 further solidified his expertise in cell and gene therapy.
Achievements
Julien Fleurence has developed significant skills in mouse model development for glioblastoma multiforme (GBM), including subcutaneous and orthotopic models. He has a strong understanding of current biotech industry trends and possesses commercial acumen. His background includes developing molecular biology methods and clinical translation in a pre-GMP research environment, enhancing his contributions to the field.